在研机构- |
最高研发阶段无进展临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
血友病A | 临床1期 | - | 2021-02-01 |
临床1期 | 4 | 繭糧觸艱淵壓簾襯顧鑰(襯餘鏇艱壓鬱遞鹽艱艱) = The HSCT procedure was well tolerated. Neutrophil and platelet engraftment occurred at 10-12 and 12-15 days after HSCT and the duration of severe neutropenia and thrombocytopenia was 7-11 and 1-4 days, respectively. There were no bleeding episodes. No Grade >2 non-hematological toxicities occurred during the engraftment period. 廠築範襯鹽製夢窪壓壓 (繭觸願鹹製廠蓋鬱壓鹹 ) | 积极 | 2024-04-23 |